We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-1.9%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$647M
AUM Growth
-$194M
Cap. Flow
+$33.7M
Cap. Flow %
5.2%
Top 10 Hldgs %
63.34%
Holding
208
New
51
Increased
38
Reduced
42
Closed
71

Top Buys

Rank Stock Value
1
NVO
Novo Nordisk
NVO
+$20.4M
2
NKTR icon
Nektar Therapeutics
NKTR
+$14.1M
3
XERS icon
Xeris Biopharma Holdings
XERS
+$8.7M
4
ESPR
Esperion Therapeutics
ESPR
+$6.56M
5
NTBL
Notable Labs, Ltd. Ordinary Shares
NTBL
+$4.27M

Top Sells

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$12M
2
BIIB icon
Biogen
BIIB
+$8.66M
3
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$3.63M
4
COGT icon
Cogent Biosciences
COGT
+$3.16M
5
INCY icon
Incyte
INCY
+$2.77M

Sector Composition

Rank Sector Weight
1 Miscellaneous 73.46%
2 Healthcare 26.22%
3 Consumer Staples 0.17%
4 Financials 0.05%
5 Industrials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NOVN
51
DELISTED
Novan, Inc. Common Stock
NOVN
$1.36M 0.21%
46,290
-8,225
-15% -$249K
PAVM icon
52
PAVmed
PAVM
$41.8M
$1.33M 0.21%
3,109
+1,089
+54% +$666K
ONCE
53
PUT
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$1.32M 0.2%
160
-855
-84% -$66K
SGMO
54
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.25M 0.19%
878
+649
+283% +$10.8K
VIRX
55
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.09M 0.17%
+14,630
New +$1.3M
VKTX icon
56
CALL
Viking Therapeutics
VKTX
$3.51B
$1.04M 0.16%
+1,094
New +$7.28K
DNTH icon
57
Dianthus Therapeutics
DNTH
$5.88B
$1.02M 0.16%
+4,738
New +$1.07M
EIDX
58
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$1.01M 0.16%
+49,833
New +$1.04M
APTX
59
DELISTED
Aptinyx Inc. Common Stock
APTX
$1.01M 0.16%
+41,857
New +$896K
RKDA icon
60
Arcadia Biosciences
RKDA
$1.04M
$1M 0.16%
3,045
-718
-19% -$392K
CTXR icon
61
Citius Pharmaceuticals
CTXR
$15.7M
$937K 0.14%
16,287
-9,361
-36% -$622K
SGYPW
62
CALL
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$914K 0.14%
5,254
+300
+6% +$52.2K
MRNS
63
CALL
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$896K 0.14%
317
+204
+181% +$4.52K
BIIB icon
64
CALL
Biogen
BIIB
$31.9B
$871K 0.13%
30
– –
TPST icon
65
Tempest Therapeutics
TPST
$12.8M
$866K 0.13%
326
-174
-35% -$458K
HYPD
66
Hyperion DeFi Inc
HYPD
$51.9M
$845K 0.13%
1,677
+455
+37% +$301K
NUWE icon
67
Nuwellis
NUWE
$2.6M
– –
0
– –
IDXG
68
DELISTED
Interpace Biosciences, Inc. Common Stock
IDXG
$830K 0.13%
93,295
+1,310
+1% +$11.6K
QNRX
69
Quoin Pharmaceuticals
QNRX
$13.6M
$798K 0.12%
1
-1
-50% -$731K
ATOS icon
70
Atossa Therapeutics
ATOS
$24.5M
$750K 0.12%
+22,717
New +$1.22M
KZR
71
DELISTED
Kezar Life Sciences
KZR
$735K 0.11%
+4,251
New +$742K
PAVMZ
72
DELISTED
PAVmed Inc. Series Z Warrant
PAVMZ
$704K 0.11%
+2,128,700
New +$1.05M
FOLD
73
CALL
DELISTED
Amicus Therapeutics
FOLD
$697K 0.11%
446
-559
-56% -$8.45K
FCEL icon
74
PUT
FuelCell Energy
FCEL
$1.21B
$695K 0.11%
15
+6
+67% +$3.94K
KYNB
75
Kyntra Bio
KYNB
$31.7M
$657K 0.1%
+420
New +$548K
1 2
3
4 5

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q2 2018 Portfolio in Review

As of Q2 2018, Sabby Management held 208 positions worth $647M, down 23% from $841M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Sabby Management deployed $33.7M of net new capital in Q2 2018, opening 51 new positions and adding to 38 existing holdings. Its largest new stake was Novo Nordisk: 858,710 shares worth $19.8M.

By sector, the portfolio is most concentrated in Miscellaneous at 73% of assets, down from 83% a quarter earlier, followed by Healthcare and Consumer Staples.

On the sell side, the largest reduction was Biogen, an estimated $8.66M trimmed.

  • Sabby Management's largest Q2 2018 buy was Novo Nordisk: 858,710 shares worth $19.8M.
  • Sabby Management added most to Nektar Therapeutics in Q2 2018, an estimated $14.1M increase.
  • Sabby Management's biggest Q2 2018 reduction was Biogen, cutting an estimated $8.66M.
  • Sabby Management fully exited State Street SPDR S&P 500 ETF Trust in Q2 2018, selling an estimated $12M.
  • Sabby Management's ten largest holdings make up 63% of its $647M portfolio in Q2 2018.
  • Sabby Management opened 51 new positions and closed 71 in Q2 2018.
  • Sabby Management's portfolio value fell 23% quarter-over-quarter to $647M.

Based on Sabby Management's 13F filing for Q2 2018, filed 14 Aug 2018.